Public Health and Economic Impact of Replacing the Sequence PCV13→PPV23 with PCV20 in the French Adult Pneumococcal Vaccination Program
Author(s)
Fiévez S1, Blanc E2, Bougeois M2, Sivignon M3, Supiot R4, Vietri J5, Perdrizet J5, Bellier L6
1Pfizer SAS France, Paris, 75, France, 2Pfizer SAS France, Paris, France, 3Putnam PHMR, Lyon, 69, France, 4Putnam PHMR, Paris, France, 5Pfizer, Inc., Collegeville, PA, USA, 6Putnam PHMR, Paris, 75, France
Presentation Documents
OBJECTIVES: Pneumococcal infections, including invasive pneumococcal disease (IPD, including meningitis and bacteraemia) and community-acquired pneumonia (CAP), are associated with an important burden in adults. The objective of this study was to evaluate the cost-effectiveness of replacing the sequential administration of 13-valent pneumococcal conjugate vaccine (PCV13) followed by pneumococcal polysaccharide vaccine (PPV23) with a single dose of the 20-valent conjugate vaccine (PCV20) in the French vaccination programme.
METHODS: A static model follows a cohort of adults at increased risk of pneumococcal disease, based on the current recommendations, vaccinated in year 1 of the simulation. Observed vaccination uptake was derived from a real-world study (COVARISQ, 2018). Higher uptake was assumed with PCV20 (+40-50 points depending on the age and risk groups) to reflect the impact of an improved prevention and simplified schedule. Epidemiological and cost data for hospitalised cases were sourced from the French National Claims Database (SNDS, 2019). Effectiveness of the vaccines were estimated based on clinical studies of PCV13 and PPV23 and the serotype coverage published by surveillance network. Protection was supposed to wane over time. Other inputs, including quality of life (QoL), were informed by the literature
RESULTS: Over a lifetime horizon, the switch from PCV13 à PPV23 to PCV20 and the increased uptake considered, would prevent additional IPD (~4,000 cases) and CAP (~55,000 cases). It would therefore translate into a gain in QoL due to the prevention of premature deaths (~7,000 deaths) and of acute episodes. In total, more than 388M€ would be saved for the management of pneumococcal infections. A strategy proposing PCV20 alone was dominant for the adult population at increased risk for pneumococcal disease overall; ICERs for select age/risk groups ranged from dominant to 5,500€ /QALY.
CONCLUSIONS: This study shows that the switch from PCV13→PPV23 to PCV20 is expected to be the dominant strategy from the French collective perspective.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
EE143
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Vaccines